-
Anastomosis Is Possible with an Acceptable Low Rate of Complications Compared to a Diverting Stoma in Surgery for Ovarian Cancer
Vibe Munk Bertelsen,
Gitte Ørtoft Lykkegård,
Lone Kjeld Petersen
Issue:
Volume 7, Issue 2, June 2019
Pages:
28-32
Received:
10 March 2019
Accepted:
25 April 2019
Published:
5 June 2019
Abstract: Radical surgery for advanced stage of ovarian cancer may lead to bowel resection and consequently either an anastomosis or a diverting stoma. This study investigates whether it is possible to find selection criteria which predict benefits from an anastomosis compared to a diverting stoma, in order to prevent complications and leakage. Consecutive patients with ovarian/tuba/peritoneal cancer undergoing initial bowel resection at Aarhus University Hospital, Denmark, between March 2012 and December 2015 were retrospectively identified. Among 67 patients with bowel resections, 32 patients had a stoma and 35 patients had an anastomosis. No significant differences were observed in the two groups regarding age, BMI, smoking, ASA classification, FIGO stage, plasma albumin, the ability to undergo radical surgery, or time to initiate chemotherapy. The length of hospital stay was longer for patients with a stoma (P=0.01). An anastomotic leakage lead to reoperation for 8.6% of the anastomosis patients. Patients who were reoperated due to leakage, initiated chemotherapy after 21-45 days. Only smoking was identified as a preoperative risk factor for leakage after bowel anastomosis in relation to debulking surgery for ovarian cancer. The complication rate among patients with an anastomosis was acceptably low, and the time from surgery to start of chemotherapy was the same as in patients with a stoma. This study supports the hypothesis that an anastomosis can be safely performed in patients with advanced ovarian cancer.
Abstract: Radical surgery for advanced stage of ovarian cancer may lead to bowel resection and consequently either an anastomosis or a diverting stoma. This study investigates whether it is possible to find selection criteria which predict benefits from an anastomosis compared to a diverting stoma, in order to prevent complications and leakage. Consecutive p...
Show More
-
MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer
Carlos Ferrer Albiach,
Enrique Ochoa Aranda,
Alfonso Gomez Iturriaga-Piña,
Amalia Sotoca Ruiz,
Fernando López Campos,
Mariano Porras Martinez,
Raquel García Gómez,
Manel Algara Lopez,
Virginia Ramos Fernandez,
Antonio Conde Moreno,
Susana Ors,
Esther Flores,
Francisco Garcia Piñón
Issue:
Volume 7, Issue 2, June 2019
Pages:
33-40
Received:
17 June 2019
Accepted:
19 July 2019
Published:
6 August 2019
Abstract: The oligometastatic status in the prostate is a new entity of metastatic patients in which their treatment allows to improve survival over standard treatments. There are several theories about their biological origin, one of them being alterations in the expression of miRNas This. was a retrospective multicentre study undertaken in patients with oligometastatic prostate cancer who were diagnosed and treated at one of 7 different Spanish healthcare centres. METHODS: The study included 22 patients; healthy and primary tumour biopsy tissue was analysed in 7+2 of them in order to determine if they had a characteristic microRNA expression profile. We quantified the expression of the following miRNAs: mir‑200a, mir‑200b, mir‑200c, mir‑210, mir‑95, mir‑96, mir‑654‑3p, mir‑543‑3p, mir‑21, mir‑16‑5p, mir‑191‑5p, and mir‑93‑5p, with the latter three being endogenous‑expression controls. RESULTS: Our results show that miRNA95, and to a lesser extent, miRNA654‑3p, were significantly underexpressed (or their expression was suppressed) in tumour tissue samples compared to normal perilesional tissue in all our patients; miRNA95 was underexpressed in 67% of the patients in our sample However, we detected no relationship between miRNA95 expression and the Gleason scores obtained for our patients. CONCLUSIONS: The simple size in our series are limited, but they do allow us to infer that there could be a specific miRNA expression signature in oligometastatic patients with prostate cancer, which may be of great interest in the development of future clinical trials and subsequent studies.
Abstract: The oligometastatic status in the prostate is a new entity of metastatic patients in which their treatment allows to improve survival over standard treatments. There are several theories about their biological origin, one of them being alterations in the expression of miRNas This. was a retrospective multicentre study undertaken in patients with ol...
Show More
-
Effect of Magnesium Supplementation to Prevent Nephrotoxicity on the Antitumor Activity of Cisplatin
Megumi Yasuda,
Shuichi Kishimoto,
Rika Ebara,
Manabu Amano,
Shoji Fukushima
Issue:
Volume 7, Issue 2, June 2019
Pages:
41-46
Received:
5 August 2019
Accepted:
24 August 2019
Published:
9 September 2019
Abstract: Background: Cisplatin (CDDP) is one of the most widely used anticancer drugs, but CDDP often leads to nephrotoxicity, which limits its clinical effectiveness. Magnesium (Mg) supplementation is recommended for the avoidance of CDDP-induced nephrotoxicity. However, there is a concern that exposing cancer cells to Mg may suppress the antitumor effect of CDDP. Methods: Transporter expression, intracellular platinum and Mg levels, and cytotoxicity of CDDP after Mg exposure were assessed in human hepatocellular carcinoma (HepG2) and human ovarian carcinoma (2008) cells. Results: In HepG2 cells, Mg exposure significantly increased mRNA levels of multidrug and toxin extrusion 1 (MATE1), which mediates the renal excretion of CDDP, but did not alter its protein levels, including those of organic cation transporter 1 (OCT1), which mediates CDDP uptake in renal tubular and cancer cells, and multidrug resistance-associated protein 2 (MRP2), which mediates CDDP efflux in cancer cells. In 2008 cells, MATE1 protein expression could not be detected, but a slight increase in MRP2 and OCT1 protein expression was observed after Mg exposure. Intracellular Mg levels were significantly increased due to Mg exposure in both cells. However, intracellular platinum levels and cytotoxicity of CDDP were not affected in both cells, even with 2 mM Mg co-exposure. Conclusion: This study found that Mg exposure only slightly changed transporter expression and did not affect intracellular platinum levels and CDDP cytotoxicity in HepG2 and 2008 cells. Thus, Mg supplementation can be used to avoid CDDP-induced renal toxicity without affecting the accumulation of CDDP in cancer cells and its cytotoxicity.
Abstract: Background: Cisplatin (CDDP) is one of the most widely used anticancer drugs, but CDDP often leads to nephrotoxicity, which limits its clinical effectiveness. Magnesium (Mg) supplementation is recommended for the avoidance of CDDP-induced nephrotoxicity. However, there is a concern that exposing cancer cells to Mg may suppress the antitumor effect ...
Show More
